Current Pharmaceutical Design
ISSN 1381-6128 · Bentham Science Publishers · United Arab Emirates · active 1969–2026
Flagged for closer checking
Publisher listed on Beall's archive (frozen 2017). Cross-check with DOAJ and Think.Check.Submit before submission.
This is a screening signal, not a verdict. How this check works.
Metrics
- Scimago quartile (2025)
- Q2
- Cites per paper (2y)
- 2.9
- SJR
- 0.632
- h-index
- 209
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 1 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Current Pharmaceutical Design is Q2 in all 2 of its subject categories.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Drug Discovery | Q2 | #71 of 161 |
| Pharmacology | Q2 | #161 of 339 |
- Cites per document (2 years, Scopus)
- 3.35
- Documents indexed in 2025 (Scopus)
- 325
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- subscription. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Current Pharmaceutical Design a predatory journal?
Our screening flags Current Pharmaceutical Design as a possible predatory venue because its publisher appears on Beall's archive, which has been frozen since 2017. Treat this as a prompt to check carefully, not a verdict: verify against DOAJ and Think. Check. Submit before submitting.
Is Current Pharmaceutical Design indexed in Scopus or Web of Science?
Per our venue index, Current Pharmaceutical Design appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Current Pharmaceutical Design?
Papers in Current Pharmaceutical Design are cited about 2.9 times each within two years of publication, and Scimago places it in Q2, with an h-index of 209. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Current Pharmaceutical Design (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Current Pharmaceutical Design is Q2 in all 2 of its subject categories. By category: Drug Discovery: Q2, #71 of 161; Pharmacology: Q2, #161 of 339. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Current Pharmaceutical Design is cited about 2.9 times per paper over two years, with an h-index of 209.
What is the Web of Science (JCR) quartile of Current Pharmaceutical Design?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Current Pharmaceutical Design. The open equivalent is its Scimago quartile, Q2, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Current Pharmaceutical Design open access?
Our index records its access status as "subscription". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Ready to submit? Tools for your next paper
Similar venues
Compare it with its peers: Ranked Molecular Biology journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.